Acrivon Therapeutics
ACRV
ACRV
48 hedge funds and large institutions have $109M invested in Acrivon Therapeutics in 2024 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 14 increasing their positions, 9 reducing their positions, and 5 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more capital invested
Capital invested by funds: $ → $
more funds holding
Funds holding: →
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.34% less ownership
Funds ownership: 69.05% → 68.7% (-0.34%)
Holders
48
Holding in Top 10
1
Calls
–
Puts
–
Top Buyers
| 1 | +$1.27M | |
| 2 | +$734K | |
| 3 | +$683K | |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$384K |
| 5 |
BBA
Baker Bros. Advisors
New York
|
+$378K |
Top Sellers
| 1 | -$1.29M | |
| 2 | -$1.11M | |
| 3 | -$243K | |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$227K |
| 5 |
JPMorgan Chase & Co
New York
|
-$203K |